Ishara Investments LP Takes Position in Vaxcyte, Inc. $PCVX

Ishara Investments LP bought a new stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX) during the fourth quarter, HoldingsChannel reports. The firm bought 50,000 shares of the company’s stock, valued at approximately $2,307,000. Vaxcyte makes up approximately 2.7% of Ishara Investments LP’s holdings, making the stock its 12th largest holding.

A number of other hedge funds also recently bought and sold shares of PCVX. Caligan Partners LP bought a new position in Vaxcyte in the 4th quarter worth about $78,660,000. Adage Capital Partners GP L.L.C. raised its position in Vaxcyte by 418.0% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 1,725,000 shares of the company’s stock worth $79,592,000 after buying an additional 1,392,000 shares during the last quarter. Polar Capital Holdings Plc raised its position in Vaxcyte by 302.6% in the 4th quarter. Polar Capital Holdings Plc now owns 1,672,783 shares of the company’s stock worth $77,182,000 after buying an additional 1,257,253 shares during the last quarter. Norges Bank purchased a new position in Vaxcyte in the 4th quarter worth about $56,703,000. Finally, Deep Track Capital LP raised its position in Vaxcyte by 39.5% in the 3rd quarter. Deep Track Capital LP now owns 3,000,000 shares of the company’s stock worth $108,060,000 after buying an additional 850,000 shares during the last quarter. Institutional investors own 96.78% of the company’s stock.

Vaxcyte Stock Performance

Shares of PCVX stock opened at $50.67 on Thursday. Vaxcyte, Inc. has a fifty-two week low of $29.08 and a fifty-two week high of $65.00. The firm has a market capitalization of $7.32 billion, a price-to-earnings ratio of -7.36 and a beta of 1.24. The stock’s 50-day simple moving average is $53.74 and its 200-day simple moving average is $52.69.

Vaxcyte (NASDAQ:PCVX) last released its earnings results on Wednesday, May 6th. The company reported ($2.30) EPS for the quarter, missing analysts’ consensus estimates of ($1.74) by ($0.56). During the same period in the previous year, the business earned ($1.04) earnings per share. As a group, equities analysts forecast that Vaxcyte, Inc. will post -7.56 earnings per share for the current year.

Wall Street Analyst Weigh In

PCVX has been the subject of several research reports. Jefferies Financial Group reaffirmed a “buy” rating on shares of Vaxcyte in a research report on Tuesday, March 10th. Weiss Ratings restated a “sell (d-)” rating on shares of Vaxcyte in a research note on Wednesday, April 8th. BTIG Research increased their target price on Vaxcyte from $85.00 to $89.00 and gave the company a “buy” rating in a research report on Wednesday, February 25th. Finally, Wall Street Zen downgraded Vaxcyte from a “sell” rating to a “strong sell” rating in a research report on Tuesday, April 28th. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $86.00.

Insider Buying and Selling

In other news, COO Jim Wassil sold 2,250 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $49.52, for a total value of $111,420.00. Following the completion of the sale, the chief operating officer directly owned 158,494 shares in the company, valued at $7,848,622.88. The trade was a 1.40% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Elvia Cowan sold 3,000 shares of the business’s stock in a transaction that occurred on Tuesday, April 7th. The shares were sold at an average price of $60.00, for a total value of $180,000.00. Following the completion of the sale, the chief accounting officer owned 28,975 shares of the company’s stock, valued at $1,738,500. This trade represents a 9.38% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 7,500 shares of company stock valued at $419,288 over the last 90 days. Company insiders own 3.30% of the company’s stock.

Vaxcyte Company Profile

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.